Agouron deal

AGPH (La Jolla, Calif.) has reaquired worldwide commercial rights to a class of HIV protease inhibitor drugs from Eli Lilly, AGPH's co-development partner for the drugs. In return, AGPH will provide Lilly with details of the three-dimensional atomic structure of a new anti-viral drug target recently discovered by AGPH scientists. AGPH said the target is an enzyme that plays an essential role in the life cycle of an undisclosed family of pathogenic viruses unrelated HIV. ...